


## New treatment

against multi resistant respiratory infections

## New perspectives with Meveol

After MRSA, Burkholderia Cepacia, Pseudomonas aeruginosa mucoïd, **the proof of efficacy of Meveol against Mycobacterium abscessus foresees the possibilities of this new treatment in the most difficult respiratory infections.**

8/09/10. Alaxia\*, announces that their **candidate Medicine** OSCN/Lactoferrin under development called **Meveol, proved its efficacy** against Mycobacterium abscessus, emergent and virulent pathogen in Cistic Fibrosis. Those very good results on a class 2 non tuberculosis mycobacteria open new promising perspectives.



*Meveol is as well efficient against Mycobacterium abscessus. This new potential treatment confirms its wide spectrum of action and its major potential interest in CF. the very good efficacy obtained leads to new perspectives for the treatment of infections with Mycobacteria, mainly tuberculoses in its most resistant forms.*

Philippe Bordeau, Alaxia CEO declared :  
« *Those very good results In Vitro on a*

*multi resistant strain of mycobacteria, with no efficient treatment so far, confirms the interest of our new therapeutic way for CF patients »*

« *this will open new ways of applications for other y multi-resistant respiratory infections.* »

Philippe Bordeau thinks about tuberculoses, and generally about all sorts of respiratory infections resistant to antibiotics.

Resistances to antibiotics: a preoccupation increasingly urgent for medical doctors and epidemiologists, this implies new efficient tools. Meveol is one of those,

### The support of EU for ALAXIA laboratory and its MEVEOL

**The European Union confirms the interest of Meveol, en deciding to support Alaxia laboratory.** A financial aid recognising the completed works and will enable to gain time for the Clinical programme.

### Alaxia : a necessary development for an innovative laboratory

The Lyon laboratory foresees to attract new partners to develop its pipe line of innovative medicine faster and widened to new pathologies.

The working force has recently been strengthened with the arrival of an MD in charge of Medical Affairs, to support the existing team comprising a PharmD specialised in R&D and another pharmacist in charge of regulatory affairs.

**Relations Presse :** Philippe LD : 04.82.53.01.68 [philippe.medias@bioalaxia.eu](mailto:philippe.medias@bioalaxia.eu)  
[www.alaxia-pharma.eu](http://www.alaxia-pharma.eu)

**About Alaxia**

Alaxia's role is to develop new therapeutic solutions for difficult respiratory diseases.

**Meveol : OSCN / Lactoferrin**

The OSCN/Lactoferrin formulation, developed by Alaxia under the name of Meveol, obtained the Orphan Medicine designation for Cystic Fibrosis in Europe (EMA) and in the US (FDA) thanks to:

- its wide spectrum antimicrobial efficacy, including multi-resistant bacteria
- its ability to break established bio films
- its having no antibiotic resistance risk
- its low toxicity.

**Mycobacterium abscessus :**

*M. abscessus* is the most common rapidly growing mycobacterium (RGM) pathogenic for man. It is by far the leading RGM causing lung infections in patients with an underlying disease (cystic fibrosis, COPD, bronchial dilatation), but also in healthy subjects free of lung disease. *M. abscessus* is also the most common RGM found in bronchial secretions in patients with cystic fibrosis.

**Cystic Fibrosis**

CF is a serious genetic disease in one child out of 3500 in France. In spite of all the progress of science there is no curing treatment up to date. Repetitive respiratory infections that make for a degradation of the pulmonary function are the main cause for death, at an average age of 24.

**Press Relations:** Philippe LD : +33 (0)4.82.53.01.68 [philippe.medias@bioalaxia.eu](mailto:philippe.medias@bioalaxia.eu)

[www.alaxia-pharma.eu](http://www.alaxia-pharma.eu)